Nilotinib is under clinical development by KeifeRx and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nilotinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nilotinib overview
Nilotinib is under development for the treatment of Parkinson's disease, Alzheimer's disease, Lewy body dementia (DLB) Huntington's disease and mild cognitive impairment (MCI). It is administered as a capsule through oral route. It acts by targeting discoidin domain-containing receptor 1 and tyrosine-protein kinase ABL1.
KeifeRx overview
KeifeRx is a life sciences company that develops novel medicines to treat neurodegenerative diseases. It is evaluating Nilotinib drug against Parkinson’s, Alzheimer’s, Lewy body dementia (LBD) and Huntington’s disease; and Bosutinib drug targeting LBD. The company is also investigating drugs to treat amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), other Parkinson plus syndromes, frontotemporal lobar dementia, corticobasal degeneration, multiple system atrophy, progressive supranuclear palsy, and prion disease. It is a spin-out from Georgetown University. KeifeRx is headquartered in Mclean, Virginia, the US.
For a complete picture of Nilotinib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
